By selectively engaging caspase-3, caspase-8, caspase-3/7, or caspase-9, RiPPs effectively disrupt cancer cell survival pathways, providing a mechanistic foundation for their therapeutic potential [171,172]. This evidence concerns the gene CASP3 and cancer.